Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Morphosys Ag ADR (NQ: MOR ) 18.96 UNCHANGED Last Price Updated: 4:00 PM EDT, Aug 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Morphosys Ag ADR < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO May 18, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 17) Alexion Pharmaceuticals, Inc... Via Benzinga Exposures COVID-19 MorphoSys and Incyte Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-line Treatment for Diffuse Large B-Cell Lymphoma May 11, 2021 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / May 11, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced that the first patient has been dosed in the pivotal... From MorphoSys AG Via AccessWire Exposures COVID-19 Product Safety Earnings Scheduled For May 5, 2021 May 05, 2021 Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter. • EyePoint Pharmaceuticals (NASDAQ:EYPT... Via Benzinga The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron May 12, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... Via Benzinga Exposures COVID-19 Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma May 11, 2021 From Incyte Via Business Wire Stocks That Hit 52-Week Lows On Tuesday May 11, 2021 Before 10 a.m. ET Tuesday, 173 stocks hit new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Snowflake (NYSE:SNOW... Via Benzinga Stocks That Hit 52-Week Lows On Monday May 10, 2021 Monday morning saw 78 companies set new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was Rocket Companies (NYSE:RKT).... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session May 10, 2021 Gainers Conformis (NASDAQ:CFMS) stock moved upwards by 29.53% to $1.09 during Monday's pre-market session. The company's market cap stands at $198.8 million. As... Via Benzinga MorphoSys AG (MOR) Q1 2021 Earnings Call Transcript May 06, 2021 MOR earnings call for the period ending March 31, 2021. Via The Motley Fool Topics Earnings Exposures Financial MorphoSys AG Reports First Quarter 2021 Results May 05, 2021 - MonjuviU.S. net product sales of € 12.9 million (US$ 15.5 million) - Tremfya royalties of € 11.6 million - Reaffirming group revenue guidance of € 150 to € 200 million - Conference call and webcast... From MorphoSys AG Via AccessWire Exposures COVID-19 Stocks That Hit 52-Week Lows On Wednesday May 05, 2021 Wednesday morning, 15 companies reached new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Vistra (NYSE:... Via Benzinga DGAP-News: Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 April 28, 2021 Conference Call Alert Invitation to MorphoSys' First Quarter Results Conference Call on May 6, 2021 MUNICH, GERMANY / ACCESSWIRE / April 28, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ: MOR), a... From MorphoSys AG Via AccessWire Exposures COVID-19 The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom May 06, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... Via Benzinga Exposures Product Safety The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex April 20, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,... Via Benzinga MorphoSys and Incyte Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma April 19, 2021 PLANEGG/MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / April 19, 2021 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) and Incyte (NASDAQ:INCY) today announced the first... From MorphoSys AG Via AccessWire Exposures COVID-19 Product Safety Incyte and MorphoSys Announce First Patient Dosed in Phase 3 inMIND Study Evaluating the Addition of Tafasitamab to Lenalidomide and Rituximab in Relapsed or Refractory Follicular or Marginal Zone Lymphoma April 19, 2021 From Incyte and MorphoSys AG Via Business Wire < Previous 1 2 ... 4 5 6 7 8 9 10 11 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
